Vitamin D and multiple sclerosis. A prospective survey of patients of Poitou-Charentes area;Vitamine D et sclérose en plaques. Étude prospective d»une cohorte de patients de la région Poitou-Charentes

Revue Neurologique

Volumn 167, Issue 4, 2011, Pages 317-323

  Neau, J P ^a   Artaud Uriot, M S ^b   Lhomme, V ^c   Bounaud, J Y ^a   Lebras, F ^b   Boissonnot, L ^b   Moinot, N ^a   Ciron, J ^a   Larrieu, D ^a   Mathis, S ^a   Godeneche, G ^a   Ingrand, P ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b Faculte de Medecine et de Pharmacie   (France)

^c Laboratoires d'Analyses de Biologie Médicale   (France)

Author keywords

Disability; Multiple Sclerosis; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; FIRST TRIMESTER PREGNANCY; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSPECTIVE STUDY; RELAPSE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

ADULT; AGED; DISABILITY EVALUATION; FEMALE; FRANCE; HEALTH SURVEYS; HUMANS; HYDROXYCHOLECALCIFEROLS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROSPECTIVE STUDIES; RECURRENCE; VITAMIN D; VITAMIN D DEFICIENCY; YOUNG ADULT;

EID: 79954420384     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2010.10.002     Document Type: Article

References (60)

1. Almirall J, Vaqueiro M, Baré ML, Anton E. Association of low serum 25-hydroxyvitamin D levels and high arterial blood pressure in the elderly. Nephrol Dial Transplant 2010;25:503-9.
2. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007;61:288-99.
3. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: noninfectious factors. Ann Neurol 2007;61:504-13.
4. Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol 2010;9:599-612.
5. Barnes M, Bonham MP, Robson PJ, Strain JJ, Lowe-Strong AS, Eaton-Evans J, et al. Assessment of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D3 concentrations in male and female multiple sclerosis patients and control volunteers. Mult Scler 2007;13:670-2. (Pubitemid 46939536)
6. Barnett CM, Nielson CM, Shannon J, Chan JM, Shikany JM, Bauer DC, et al. Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes Control. 2010;21:1297-1303.
7. Becklund BR, Severson KS, Vang SV, DeLuca HF. UV radiation suppresses experimental autoimmune encephalomyelitis independent of vitamin D production. Proc Natl Acad Sci U S A 2010;107:6418-23.
8. Beretich BD, Beretich TM. Explaining multiple sclerosis prevalence by ultraviolet exposure: a geospatial analysis. Mult Scler 2009;15:891-8.
9. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006;84:18-28. (Pubitemid 44699167)
10. Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010;74:1852-9.
11. Chapuy MC, Preziosi P, Maamer M, Arnaud S, Galan P, Hercberg S, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporosis Int 1996;7:439-43.
12. Correale J, Ysrraelit MC, Gaitan MI. Immunomodulatory aspects of vitamin D in multiple sclerosis. Brain 2009;132:1146-60.
13. Fardellone P, Sebert JL, Bouraya M, Bonidan O, Leclercq G, Doutrellot C, et al. Evaluation of the calcium content of diet by frequential self-questionnaire. Rev Rhum Mal Osteoartic 1991;58:99-103.
14. Fromont A, Binquet C, Clerc L, Moreau T. Épidémiologie de la sclérose en plaques : la particularité française. Rev Neurol (Paris) 2009;165:671-5.
15. Fromont A, Binquet C, Sauleau EA, Fournel I, Bellisario A, Adnet J, et al. Geographic variations of multiple sclerosis in France. Brain 2010;133:1889-99.
16. Goldberg P, Fleming MC, Picard EH. Multiple sclerosis: decreased relapse rate through dietary supplementation with c alcium, magnesium and vitamin D. Med Hypotheses 1986;21:193-200. (Pubitemid 17201931)
17. Gouni-Berthold I, Krone W, Berthold HK. Vitamin D and cardiovascular disease. Curr Vasc Pharmacol 2009;7:414-22.
18. Hanwell HE, Vieth R, Magalhaes M, McGowan M, Marrie RA, Bar-Or A, et al. Vitamin D status as a predictor of multiple sclerosis outcome following an initial pediatric demyelinating event. Mult Scler 2009;15(Suppl 2):S40-1.
19. Harpavat M, Keljo DJ, Regueiro MD. Metabolic bone disease in inflammatory bowel disease. J Clin Gastroenterol 2004;38:218-24. (Pubitemid 38233328)
20. Hiremath GS, Cettomai D, Baynes M, Ratchford JN, Newsome S, Harrison D, et al. Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis. Mult Scler 2009;15:735-40.
21. Holick MF. The Vitamin D epidemic and its health consequences. J Nutr 2005;135:2739S-48S.
22. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81.
23. Holmøy T, Moen SM, Gundersen TA, Holick MF, Fainardi E, Castellazzi M, et al. 25-hydroxyvitamin D in cerebrospinal fluid during relapse and remission of multiple sclerosis. Mult Scler 2009;15:1280-5.
24. Hughes DA, Norton R. Vitamin D and respiratory health. Clin Exp Immunol 2009;158:20-5.
25. Hyppönen E, Power C. Hypovitaminosis D in British adults at age 45 yrs: nationwide cohort study of dietary and lifestyle predictors. Am J Clin Nutr 2007;85:860-8. (Pubitemid 46393520)
26. Kampman MT, Wilsgaard T, Mellgren SI. Outdoor activities and diet in childhood and adolescence relate to MS risk above the Artic Circle. J Neurol 2007;254:471-7. (Pubitemid 46786722)
27. Kampman MT, Brustad M. Vitamin D: a candidate for the environmental effect in multiple sclerosis-observations from Norway. Neuroepidemiology 2008;30:140-6. (Pubitemid 351667793)
28. Kanazawa I, Yamaguchi T, Hayashi K, Takase H, Shimizu T, Sugimoto T. Effects of treatment with risedronate and alfacalcidol on progression of atherosclerosis in postmenopausal women with type 2 diabetes mellitus accompanied with osteoporosis. Am J Med Sci 2010;339:519-24.
29. Kayaniyil S, Vieth R, Retnakaran R, Knight JA, Qi Y, Gerstein HC, et al. Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care 2010;33:1379-81.
30. Kimball SM, Ursell MR, O'Connor P, Vieth R. Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr 2007;86:645-51. (Pubitemid 47435831)
31. Kragt J, van Amerongen B, Killestein J, Dijkstra CD, Uitdehaag BMJ, Polman CH, et al. Higher levels of 25-hydryvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult Scler 2008;14:1-5.
32. Leventis P, Patel S. Clinical aspects of vitamin D in the management of rheumatoid arthritis. Rheumatology (Oxford) 2008;47:1617-21.
33. McDowell TY, Amr S, Langenberg P, Royal W, Bever C, Culpepper WJ, et al. Time of birth, residential solar radiation and age at onset of multiple sclerosis. Neuroepidemiology 2010;34:238-44.
34. Mehan TF, DeLuca HF. The vitamin D receptor is essential for 1alpha,25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. Arch Biochem Biophys 2002;408:200-4.
35. Mehta BK. New hypotheses on sunlight and the geographic variability of multiple sclerosis prevalence. J Neurol Sci 2010;292:5-10.
36. Mehta S, Giovannucci E, Mugusi FM, Spiegelman D, Aboud S, Hertzmark E, et al. Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS One 2010;5:e8770.
37. Mowry EM, Krupp LB, Milazzo M, Chabas D, Strober JB, Belman AL, et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 2010;67:618-24.
38. Munger KL, Zhang SM, O'Reilly E, Hernan MA, Olek MJ, Willet WC, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004;62:60-5.
39. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296:2832-8. (Pubitemid 44969183)
40. Myhr KM. Vitamin D treatment in multiple sclerosis. J Neurol Sci 2009;286:104-8.
41. Noonan CW, Williamson DM, Henry JP, Indian R, Lynch SG, Neuberger JS, et al. The prevalence of multiple sclerosis in 3 US communities. Prev Chronic Dis 2010;7:A12.
42. Pierrot-Deseilligny C. Clinical implications of a possible role of vitamin D in multiple sclerosis. J Neurol 2009;256:1468-79.
43. Pierrot-Deseilligny C, Souberbielle JC. Is hypovitaminosis D one of the environmental risk factors for multiple sclerosis? Brain 2010;133:1869-88.
44. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-6.
45. Simpson Jr S, Taylor B, Blizzard L, Ponsonby AL, Pitas F, Tremlett H, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010;68:193-203.
46. Sloka S, Pryse-Philipps J, Stefanelli M. The relation of ultraviolet radiation and multiple sclerosis in Newfoundland. Can J Neurol Sci 2008;35:69-74. (Pubitemid 351518291)
47. Smolders J, Damoiseaux J, Menheere P, Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol 2008;194:7-17.
48. Smolders J, Menheere P, Kessels A, Damoiseaux J, Hupperts R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 2008;14:1-5.
49. Soilu-Hänninen M, Airas L, Monnonen I, Heikkilä A, Viljanen N, Hänninen A. 25-hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult Scler 2005;11:266-71. (Pubitemid 40775180)
50. Soilu-Hänninen M, Laaksonen M, Laitinen I, Erälinna J-P, Lillius E-M, Mononen I. A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008;79:152-7. (Pubitemid 351236545)
51. Spach KM, Hayes CE. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J Immunol 2005;175:4119-26. (Pubitemid 41292076)
52. Steffensen LH, Mellgren SI, Kampman MT. Predictors and prevalence of low bone mineral density in fully ambulatory persons with multiple sclerosis. J Neurol 2010;257:410-8.
53. Stolzenberg-Solomon RZ, Jacobs EJ, Arslan AA, Qi D, Patel AV, Helzlsouer KJ, et al. Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol 2010;172:81-93.
54. Urashima M, Segawa T, Okazaki M, Kurihara M, Wada Y, Ida H. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am J Clin Nutr 2010;91:1255-60.
55. Van der Mei IA, Ponsonby AL, Blizzard L, Dwyer T. Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. Neuroepidemiology 2001;20:168-74. (Pubitemid 32718873)
56. Van der Mei IA, Ponsonby AL, Dwyer T, Blizzard L, Taylor BV, Kilpatrick T, et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania Australia. J Neurol 2007;254:581-90. (Pubitemid 46781963)
57. Van der Mei IA, Ponsonby AL, Engelsen O, Pasco JA, McGrath JJ, Eyles W, et al. The high prevalence of vitamin D insufficiency across Australian population is only partly explained by season and latitude. Environ Health Perspect 2007;115:1132-9. (Pubitemid 351802343)
58. Vukusik S, Van Bokstael V, Gosselin S, Confavreux C. Regional variations of multiple sclerosis prevalence in French farmers. J Neurol Neurosurg Psychiatry 2007;78:707-9. (Pubitemid 46998840)
59. Wingerchuk DM, Lesaux J, Rice GP, Kremenchutzky M, Ebers GC. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2005;76:1294-6.
60. Wingerchuk DM. Supplementing our understanding of vitamin D and multiple sclerosis. Neurology 2010;74:1846-7.